m+Medelevator.RU
← Поиск публикаций
Liver cancer · 2018

Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition).

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Zhou Jian, Sun Hui-Chuan, Wang Zheng, Cong Wen-Ming, Wang Jian-Hua, Zeng Meng-Su, Yang Jia-Mei, Bie Ping, Liu Lian-Xin, Wen Tian-Fu, Han Guo-Hong, Wang Mao-Qiang, Liu Rui-Bao, Lu Li-Gong, Ren Zheng-Gang, Chen Min-Shan, Zeng Zhao-Chong, Liang Ping, Liang Chang-Hong, Chen Min, Yan Fu-Hua, Wang Wen-Ping, Ji Yuan, Cheng Wen-Wu, Dai Chao-Liu, Jia Wei-Dong, Li Ya-Ming, Li Ye-Xiong, Liang Jun, Liu Tian-Shu, Lv Guo-Yue, Mao Yi-Lei, Ren Wei-Xin, Shi Hong-Cheng, Wang Wen-Tao, Wang Xiao-Ying, Xing Bao-Cai, Xu Jian-Ming, Yang Jian-Yong, Yang Ye-Fa, Ye Sheng-Long, Yin Zheng-Yu, Zhang Bo-Heng, Zhang Shui-Jun, Zhou Wei-Ping, Zhu Ji-Ye, Liu Rong, Shi Ying-Hong, Xiao Yong-Sheng, Dai Zhi, Teng Gao-Jun, Cai Jian-Qiang, Wang Wei-Lin, Dong Jia-Hong, Li Qiang, Shen Feng, Qin Shu-Kui, Fan Jia

Аннотация

BACKGROUND: Hepatocellular carcinoma (HCC) (about 85-90% of primary liver cancer) is particularly prevalent in China because of the high prevalence of chronic hepatitis B infection. HCC is the fourth most common malignancy and the third leading cause of tumor-related deaths in China. It poses a significant threat to the life and health of Chinese people.

SUMMARY: This guideline presents official recommendations of the National Health and Family Planning Commission of the People's Republic of China on the surveillance, diagnosis, staging, and treatment of HCC occurring in China. The guideline was written by more than 50 experts in the field of HCC in China (including liver surgeons, medical oncologists, hepatologists, interventional radiologists, and diagnostic radiologists) on the basis of recent evidence and expert opinions, balance of benefits and harms, cost-benefit strategies, and other clinical considerations.

KEY MESSAGES: The guideline presents the Chinese staging system, and recommendations regarding patients with HCC in China to ensure optimum patient outcomes.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты